CeriBell, Inc. (CBLL) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

CeriBell, Inc. (CBLL) Healthcare & Pipeline Overview

CeriBell, Inc. develops and markets the Ceribell System, an AI-driven point-of-care EEG platform designed for rapid detection of neurological conditions in acute care settings. With a focus on improving patient outcomes through innovative medical devices, CeriBell operates within the competitive medical device industry, emphasizing ease of use and speed of diagnosis.

What Is the Investment Thesis for CBLL?

CeriBell, Inc. presents a notable research candidate within the medical device sector, driven by its innovative Ceribell System. The company's AI-powered EEG platform addresses a critical need for rapid neurological assessment in acute care settings. With a gross margin of 87.9%, CeriBell demonstrates strong potential for profitability as it scales its operations. Key growth catalysts include expanding market penetration within hospitals and emergency rooms, as well as securing additional regulatory approvals for new applications of its technology. However, the company's negative profit margin of -60.0% indicates ongoing investments in R&D and market expansion, which could pose a risk if not managed effectively. The company's beta of 0.93 suggests that the stock is slightly less volatile than the overall market.

Based on FMP financials and quantitative analysis

CBLL Key Highlights

Market Cap of $944M reflects investor confidence in CeriBell's growth potential within the medical device market.

• Gross Margin of 87.9% indicates strong pricing power and efficient cost management in the production of the Ceribell System.
• Negative Profit Margin of -60.0% suggests ongoing investments in research and development and market expansion.
• Beta of 0.93 indicates that the stock is slightly less volatile than the overall market.
• AI-driven EEG platform addresses a critical need for rapid neurological assessment in acute care settings.

Who Are CBLL's Competitors?

CBLL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CBLL's Key Strengths?

Innovative AI-powered EEG technology.

• Point-of-care solution for rapid neurological assessment.
• High gross margin (87.9%).
• Strong market position in acute care settings.

What Are CBLL's Weaknesses?

Negative profit margin (-60.0%).

• Limited product portfolio.
• Dependence on regulatory approvals.
• Relatively small company size.

What Could Drive CBLL Stock Higher?

Potential FDA approval for expanded use of Ceribell System in pediatric patients.

• Increasing adoption of Ceribell System in hospitals and emergency rooms.
• Expansion of sales and marketing efforts in new geographic regions.
• Publication of clinical studies demonstrating the efficacy of the Ceribell System.

What Are the Key Risks for CBLL?

Negative return on equity (-38.2%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Competition from established medical device companies.
• Technological obsolescence of the Ceribell System.
• Changes in healthcare regulations affecting reimbursement rates.
• Economic downturn affecting hospital budgets.
• Negative profit margin due to ongoing investments in R&D and market expansion.

What Are the Growth Opportunities for CBLL?

• Expansion into New Geographic Markets: CeriBell has the opportunity to expand its market presence beyond its current focus areas. By targeting new geographic regions, particularly in Europe and Asia, the company can tap into a larger pool of potential customers. The global EEG market is projected to reach $1.5 billion by 2028, providing a substantial opportunity for CeriBell to increase its revenue and market share through strategic international expansion. Timeline: 2-3 years.
• Development of New Applications for the Ceribell System: CeriBell can leverage its AI-powered EEG platform to develop new applications for diagnosing and monitoring various neurological conditions. This includes expanding into areas such as epilepsy management, sleep disorder diagnosis, and cognitive assessment. By broadening the scope of its product offerings, CeriBell can attract a wider range of customers and increase its revenue streams. The market for neurological disorder diagnostics is estimated to grow to $12 billion by 2027. Timeline: 3-5 years.
• Strategic Partnerships with Hospitals and Healthcare Systems: CeriBell can establish strategic partnerships with hospitals and healthcare systems to integrate its Ceribell System into their standard clinical workflows. By collaborating with key stakeholders in the healthcare industry, the company can gain access to a larger customer base and accelerate the adoption of its technology. These partnerships can also provide valuable feedback for product development and improvement. Timeline: Ongoing.
• Securing Additional Regulatory Approvals: CeriBell can pursue additional regulatory approvals for its Ceribell System in various countries and regions. By obtaining these approvals, the company can expand its market access and increase its credibility with healthcare providers. Regulatory approvals also serve as a barrier to entry for competitors, strengthening CeriBell's competitive position. Timeline: Ongoing.
• Integration with Telemedicine Platforms: CeriBell can integrate its Ceribell System with telemedicine platforms to enable remote neurological assessments. This integration would allow healthcare providers to monitor patients' brain activity from a distance, improving access to care for patients in remote or underserved areas. The telemedicine market is experiencing rapid growth, driven by the increasing demand for remote healthcare services. Timeline: 1-2 years.

What Are CBLL's Competitive Advantages?

• Proprietary AI algorithms for EEG data analysis.
• Patented Ceribell System design and technology.
• Established relationships with hospitals and healthcare providers.
• First-mover advantage in the point-of-care EEG market.

What Does CBLL Do?

CeriBell, Inc., formerly known as Brain Stethoscope, Inc., was founded in 2014 and is headquartered in Sunnyvale, California. The company focuses on developing and commercializing innovative medical devices centered around electroencephalography (EEG) technology. CeriBell's core product is the Ceribell System, an AI-powered point-of-care EEG platform designed to address the unmet needs of patients in acute care settings. This system enables rapid assessment of brain activity, facilitating quicker diagnosis and treatment of neurological conditions such as seizures and stroke. The Ceribell System includes a disposable EEG headband, a compact, battery-operated recorder, and an AI-driven software platform that analyzes EEG data in real-time. The company's technology aims to simplify the EEG process, making it accessible to a broader range of healthcare providers and improving patient outcomes by enabling faster clinical decision-making. CeriBell's products are primarily targeted at hospitals, emergency rooms, and intensive care units. By integrating AI into EEG technology, CeriBell seeks to transform the way neurological conditions are diagnosed and managed in acute care environments.

What Products and Services Does CBLL Offer?

• Develop AI-based point-of-care EEG technology.
• Offer the Ceribell System, a novel EEG platform for acute care.
• Provide EEG disposable headbands for use with the Ceribell System.
• Manufacture pocket-sized battery-operated recorders for EEG data capture.
• Focus on detecting and treating neurological conditions.
• Improve the speed and accuracy of EEG analysis in acute settings.
• Provide real-time EEG data analysis through AI-driven software.

How Does CBLL Make Money?

• Sales of the Ceribell System, including hardware (recorder) and software.
• Recurring revenue from the sale of disposable EEG headbands.
• Service and maintenance contracts for the Ceribell System.
• Potential for future revenue from data analytics and AI-driven insights.

What Industry Does CBLL Operate In?

CeriBell, Inc. operates within the medical device industry, specifically focusing on neurological diagnostics. The market for EEG technology is growing, driven by the increasing prevalence of neurological disorders and the need for faster, more accurate diagnostic tools. The competitive landscape includes established medical device companies and emerging players specializing in AI-powered diagnostics. CeriBell differentiates itself through its point-of-care EEG platform, which simplifies the EEG process and enables rapid assessment in acute care settings. The company's success depends on its ability to secure regulatory approvals, expand its market reach, and maintain a competitive edge through continuous innovation.

Who Are CBLL's Key Customers?

• Hospitals and acute care facilities.
• Emergency rooms and intensive care units.
• Neurologists and other healthcare professionals specializing in neurological disorders.
• Patients requiring rapid neurological assessment.

CeriBell, Inc. Financial Trajectory

CeriBell, Inc. (CBLL) reported $28.1M in revenue for Q2 2026, reflecting 6.1% growth compared to the prior quarter. The company recorded a net loss of $19.3M, with diluted EPS of $-0.51. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this small-cap Healthcare company. Across the four most recent quarters, CBLL averaged $-0.44 in diluted EPS.

Company Profile

CeriBell, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Sunnyvale, US. The company is led by CEO Xingjuan Chao. CBLL has traded publicly since 2024.

How CeriBell, Inc. Is Valued

CeriBell, Inc. carries a market capitalization of $944M, placing it in the small-cap category. Relative to its peer group, CBLL's quantitative score of 27/100 is below the peer average of 73/100.

Return on equity for CeriBell, Inc. stands at -38.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -33.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -7.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 10.30 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -8.6%, the inverse of the P/E and a quick read on earnings relative to price.

CeriBell, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 12.93 places it in the safe zone, indicating low near-term bankruptcy risk.

CeriBell, Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 17.6% below estimates on average.

Wall Street analysts project CeriBell, Inc. revenue of about $114.0M for fiscal 2026, with EPS near $-1.71. The estimate reflects 6 contributing analysts.

CBLL Financials

CBLL Latest News

CBLL Analyst Consensus

CBLL MoonshotScore

CeriBell, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources